US FDA says Interquim's API plant remediation plan is inadequate

By Gareth Macdonald

- Last updated on GMT

Interquim facility in Barcelona, Spain (source Google maps)
Interquim facility in Barcelona, Spain (source Google maps)

Related tags Active pharmaceutical ingredients Pharmaceutical drug Food and drug administration

The US FDA has asked Spanish API firm Interquim S.A. for more details of its plan to bring its Barcelona manufacturing plant up to code.

The US regulator made the request in a warning letter​ today, explaining that Interquim ‘s plan to address problems with cleaning procedures identified during an inspection in May does not provide sufficient detail.

The agency acknowledged that Interquim has changed its protocols but said the firm has not demonstrated that the revised procedures are effective.

The Food and Drug Administration (FDA) also said the firm’s efforts to ensure equipment surfaces do not impact the quality of the raw materials, active pharmaceutical ingredients (APIs) and intermediates with which they come into contact with are inadequate.

The regulator also pointed out that Interquim’s quality unit had failed “to ensure that there is stability data to support retest or expiry dates and storage conditions on API and or intermediates​.”

Interquim is a division of Ferrer HealthTech. The firm did not respond to a request for comment.

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...